Catherine Dutreix

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

Thomas Fischer, Richard M. Stone, Daniel J. DeAngelo et al. · Journal of Clinical Oncology · 2010 · 502 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

Richard M. Stone, Thomas Fischer, Ron Paquette et al. · Leukemia · 2012 · 273 citations · Full text

Medicine, Hematology, Oncology +13

Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C

David Propper, A. McDonald, A. Man et al. · Journal of Clinical Oncology · 2001 · 233 citations

Pharmacy, Oncology, Pharmacology +15

Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion

Bin Peng, Catherine Dutreix, Günther H. Mehring et al. · The Journal of Clinical Pharmacology · 2004 · 167 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

S G O'Brien, P Meinhardt, Epperson E. Bond et al. · British Journal of Cancer · 2003 · 155 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15